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ABSTRACT
In the present study, several 2-(4-aminophenyl)-5-substituted 
amino-1,3,4-thiadiazoles (2a-l) and their coupling products, 
2,3,4-pentanetrione-3-[4-(5-alkyl/arylamino-1,3,4-thiadiazole-
2-yl)phenyl]hydrazones (3a-j) were synthesized in good yields 
and characterized by UV, IR, 1H-NMR, mass and elemental 
analysis. Antitubercular activity of the synthesized compounds 
was determined in vitro using the BACTEC 460 Radiometric 
System against Mycobacterium tuberculosis H37Rv at 6.25 
μg/mL. The antimycobacterial data of screened compounds 
indicated that 2-(4-aminophenyl)-5-(4-chlorophenyl)amino-
1,3,4-thiadiazole 2f demonstrated the highest inhibition. 
Keywords: 1,3,4-thiadiazole, coupling products, 
antimycobacterial activity
1. Introduction
Tuberculosis (TB) is a serious threat to global public health with 
9.6  million new cases of infection and 1.5 million TB-related 
deaths in 2014 (1).   Early detection of the ethiologic agent-
Mycobacterium tuberculosis is the key to successful treatment 
and reduction of disease transmission. To date, treatment, 
prophylaxis and control of  TB infection is mainly dependent 
on the use of first (isoniazid, rifampicin, pyrazinamide, 
and ethambutol) and second line drugs (ethionamide, 
prothionamide, thioacetazone, isoxyl, amikacin, kanamycin 
or capreomycin and some  fluoroquinolone derivatives as 
ofloxacin, levofloxacin, moxifloxacin and gatifloxacin) but 
increasing resistance to at least isoniazid and rifampicin was 
revealed the multidrug-resistant (MDR) tuberculosis (TB) 
(2). In 2006, the first report concerning extensively drug-
resistant TB (XDR-TB) was published and this new case 
was explained as TB caused by MDR strains  that are also 
resistant to any fluoroquinolone (FQ) and any of the second-
line injectable drugs, such as capreomycin, kanamycin, or 
amikacin (3). Here upon WHO has recommended the use 
of bedaquiline and delamanid  (previously OPC-67863) (1). 
Bedaquiline received approval from the US Food and Drug 
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Administration in December 2012 and delamanid received 
approval from the European Medicines Agency and Japan’s 
Pharmaceuticals Medical Devices Agency in 2014 (4). 
All these mentioned drugs that have been already approved 
for TB theraphy are composed of diverse  chemical entities 
and mechanisms of actions. Since last decade, the researchers 
have developed several compound series originated from 
target-based screening efforts as nitroimidazopyrans (PA-
824),  oxazolidinones (linezolid, sutezolid,   posizolid), 
1,2-ethylenediamine-based compound-SQ109, benzothiazinones 
(BTZ038, PBTZ169), Imidazopyridine amides (Q203) (5, 6). 
In addition to the mentioned chemical entities, compounds 
with 1,3,4-thiadiazole structure are also the subjects of efforts 
to identify new anti TB drugs and they are being investigated 
in significant number of works (7-9). Some representatives of 
1,3,4-thiadiazole compounds with promising antituberculosis 
activity were shown in Figure 1.
Figure 1. Some representative 1,3,4-thiadiazoles with 
promising activity against Mycobacterium tuberculosis 
H37Rv.
In the light of encouraging literature data; we synthesized 
novel 1,3,4-thiadiazole compounds and evaluated them for 
their anti-TB activity against Mycobacterium tuberculosis 
H37Rv.
2. Chemistry
In the first part of our research, benzoyl chloride and 
ethyl 4-aminobenzoate were reacted according to the 
literatüre (10). The obtained product was refluxed 
with hydrazine hydrate to prepare 4-(benzoylamino)
benzoylhydrazine. 1-[4-(Benzoylamino)benzoyl]-4 alkyl-/
arylthio-semicarbazides (1a-l) were then gained by 
condensing methyl, ethyl, propyl, cyclohexyl, phenyl, 
benzyl, 4-fluorophenyl, 4-chlorophenyl, 2-methylphenyl, 
4-methylphenyl, 4-methoxyphenyl and 4-nitrophenyl 
isothiocyanates to 4-(benzoylamino)benzoylhydrazine 
(11). From 1a-l, 2-(aminophenyl)-5-alkyl/arylamino-
1,3,4-thiadiazoles (2a-l) were synthesized by acid catalyzed 
cyclization. In the second part, 2,3,4-pentanetrione-3-[4-(5-
alkyl/arylamino-1,3,4-thiadiazole-2-yl)phenyl]hydrazones 
(3a-j) were obtained through the coupling reaction of 
acetylacetone and the diazonium salts of aromatic primary 
amines (2a-l) (12). The synthetic route to 2a-l and 3a-j is 
presented in Scheme 1.
Compounds 2a-f, had been described previously by Rollas 
(13) and Özger (14). The researchers have obtained these 
compounds at the end of a six steps reaction procedure 
by reducing 2-substituted amino-5-[p-(1’-phenyl-3’,5’-
dimethyl-4’-(1H)-pyrazolylazo)phenyl]-1,3,4-thiadiazoles 
with hydrazine hydrate without catalyst in ethanolic 
medium. On the other hand; we have achieved compounds 
2a-l by employing a short and economical reaction 
procedure comprising of four steps. According to our new 
reaction procedure; 1-[4-(benzoylamino)benzoyl]-4-alkyl-/
arylthiosemicarbazides (1a-l) were heated in 50% H2SO4 
solution at 110-150 °C.
The purity of the synthesized compounds was determined 
by HPLC. The structures of the synthesized 2g-l  and 3a-j  
were confirmed using UV, IR, 1H-NMR and MS spectral data 
besides elemental analysis.
Scheme 1. Synthetic route to the compounds 2a-l and 3a-j
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3. In vitro evaluation of antimycobacterial activity against 
M. tuberculosis H37Rv
Primary screen was conducted at 6.25 mg/mL against M. 
tuberculosis H37Rv in BACTEC 12B medium using the 
BACTEC 460 radiometric system (15, 16). Compounds 
denoting < 90% inhibition in the primary screen ( MIC > 
6.25 µg/mL ) are not considered for further evaluation. 
Compounds demonstrating at least 90% inhibition in the 
primary screen are re-tested at lower concentrations (MIC) in 
a broth microdilution assay alamar Blue. The MIC is defined 
as the lowest concentration inhibiting 99% of the inoculum.
BACTEC radiometric method of susceptibility testing. 
Inocula for susceptibility testing were either from a positive 
BACTEC isolation vial with a growth index (GI) of 500 or 
more, or a suspension of organisms isolated earlier on a 
conventional medium. The culture was mixed with a syringe 
and 0.1 ml of a positive BACTEC culture was added to each of 
the vials containing the test drugs. The drug vials contained 
rifampin (0.25 µg/mL). A control vial was inoculated with a 
1:100 dilution of the culture. A suspension equivalent to a Mc 
Farland no. 1 standart was prepared in the same manner as 
a BACTEC positive vial, when growth from a solid medium 
was used. 
Each vial was tested immediately on a BACTEC instrument to 
provide CO2 in the headspace. The vials were incubated at 37 
oC and tested daily with a BACTEC instrument. When the GI 
in the control reads at least 30, the increase in GI (DGI) from 
the previous day in the control was compared with that in the 
drug vial. The following formula was used to interpret results: 
	 DGI control  > DGI drug = susceptible
	 DGI control < DGI drug = resistant
If a clear susceptibility pattern (the difference of DGI of 
control and the drug bottle) was not seen at the time the 
control GI is 30 the vials read for 1 or 2 additional days to 
establish a definite pattern of DGI differences.
4. Results and discussion 
A series of 2-(4-aminophenyl)-(5-substituted amino)-
1,3,4-thiadiazoles (2a-l) and their coupling products (3a-j) 
have been synthesized and their antitubercular activity was 
determined in vitro using the BACTEC 460 Radiometric 
System against M. tuberculosis H37Rv at 6.25 mg/mL.
The structures of the synthesized compounds were 
determined on the basis of spectral data analysis; such as UV, 
IR, 1H-NMR and MS. 
Investigations on IR spectra of compounds 2a-l revealed that 
there were no bands characterising amide moiety but bands 
at 3483 - 3401 cm-1 and 3401 - 3282 cm-1 could be dedicated to 
asymmetric and symmetric stretching vibrations of primary 
aromatic amine respectively. 
According to the 1H-NMR spectra of the compounds 2a-l; 
the singlet signals between 3.10- 5.83 ppm  possessing the 
integration of 2H were attributed to primary aromatic amine. 
The N-H protons of secondary amine were determined 
between 8.16-13.84 ppm as singlet with the integration of 1H 
(16- 18). 
The IR spectra of compounds 3a-j exhibited hydrazone 
(-NH–N=C<) group at 3201-3166  cm-1 and carbonyl groups 
of acetyl moiety  >C=O bands at the 1689-1666 cm-1 ve 1655-
1625 cm-1 (20). The absorption bands of other functional 
groups also appeared in the expected regions.
1H-NMR spectra of the cyclization products 3a-j displayed 
the resonances of hydrazone N–H at 13.02-14.75 ppm and 
methyl protons at 2.41-2.54 ve 2.52-2.64 ppm except for 
compounds 3e and 3g. Methyl protons of compounds 3e and 
3g were determined as singlets at 2.57 ppm and 2.52 ppm 
possesing integration equivalent to 6H respectively (21).
EI-MS spectra of 2a-l showed molecular ion (M+) peaks 
which confirmed their molecular weights. In the EI-MS 
spectra of compounds 3a-j (except for compound 3f) detected 
molecular ions (M+) peaks confirmed their molecular 
weights. The common fragmentation pathway of these 
compounds was existed by the cleavage between nitrogen 
atoms of  hydrazone moiety (12, 22). CI-MS spectrum of 
compound 3f revealed nearly the same cleavage pathways as 
compounds 3a-j.  Fragmentation patterns of thiadiazole ring 
were found in accordance with the literatüre (11, 18).
Scheme 2. Proposed mass fragmentation pathways of 
compounds 3a-j.
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The synthesized compounds 2a-l and 3a-j were tested for 
antimycobacterial activity against Mycobacterium tuberculosis 
H37Rv. As provided in antituberculosis data which was 
reported in Table 1, among the 2-(4-aminophenyl)-5-
alkyl/arylamino-1,3,4-thiadiazole series 2a-l, the 4-chloro 
substituted compound 2f showed the highest inhibition. The 
4-nitro substituted compound 2l showed 37% inhibition. 
The benzyl substituted compound 2g was as active as 
compound 2l. The methyl and ethyl substituted compounds 
2a and 2b also exhibited inhibition however the propyl 
substituted compound 2c did not show any inhibition. The 
2-methyl- substituted compound  2i displayed no inhibition, 
either. The 4-methyl-substituted compound 2j showed 22% 
inhibition.
The highest inhibition in the hydrazone series 3a-j was 
observed for derivatives bearing an alkyl group at the 
5th- position of the thiadiazole ring. Longer alkyl chains 
caused a decrease in inhibition. Compounds 3a-c bearing 
methyl, ethyl, propyl groups respectively showed higher 
inhibition than their corresponding amine derivatives 2a-c. 
Compounds 3d and 3f bearing cyclohexyl, 4-chlorophenyl 
groups respectively showed lower inhibition than their 
corresponding amine derivatives 2d and 2f.
Table 1. Primary antitubercular activity screening results of 
2a-l and 3a-j
Compounds R(Ar) MIC (mg/mL) Inhibition 
(%)
2a CH3 >6.25 29
2b C2H5 >6.25 34
2c C3H7 >6.25 0
2d C6H11 >6.25 41
2e C6H5 >6.25 16
2f C6H5-Cl(4) >6.25 57
2g CH2-C6H5 >6.25 37
2h C6H5-F(4) >6.25 3
2i C6H5-CH3(2) >6.25 0
2j C6H5-CH3(4) >6.25 22
2k C6H5-OCH3(4) >6.25 7
2l C6H5-NO2(4) >6.25 37
3a CH3 >6.25 46
3b C2H5 >6.25 39
3c C3H7 >6.25 36
3d C6H11 >6.25 11
3e C6H5 >6.25 0
3f C6H5-Cl(4) >6.25 15
3g CH2-C6H5 >6.25 0
3h C6H5-F(4) >6.25 0
3i C6H5-CH3(2) >6.25 5
3j C6H5-CH3(4) >6.25 0
Rifampicin 0.25 98
5. Experimental 
Acetylacetone, benzocaine and hydrazine hydrate were 
purchased from Merck. All other chemicals were purchased 
from Fluka. Melting points were determined by using 
a Büchi-530 melting point apparatus (open capilleries) 
and were uncorrected. UV spectra were determined on a 
Shimadzu UV 2100 S spectrophotometer. IR spectra were run 
on a Perkin Elmer 1600 spectrophotometer as KBr pellets. 
1H-NMR spectra were obtained on a Bruker DP X-400 
spectrometer at MHz using TMS as the internal reference. 
Mass spectra were determined at 70 eV on a VG Zabspec 
Double Focussing Magnetic Sector spectrometer. 
HPLC apparatus and conditions: All measurements were 
performed by HPLC apparatus consisting of a Waters 
Model 600 pump, a Waters Model 481 UV dedector and a 
Rheodyne Model 7725 injector. An integrator (Unicam 4880 
Chromatography Data Handling System) was used for data 
collection. A reversed-phase m-Bondapak C18 column (150 
mm x 3.9 mm ID; Waters Assoc. Milford, MA, USA) was used 
for the analysis. The mobile phase consisted of acetonitrile-
water (60:40, v/v). The solvent flow-rate was 0.6 mL/min. The 
mobile phase was degassed in an ultrasonic bath (Bransonic 
221) prior to use. The UV  detector was set at 254 nm. 
5.1. General procedure for the preparation of 
1-[4-(be nz oylamino)be nz oyl]-4-alkyl- /ar ylthio-
semicarbazides (1a-l)
Compound 4-(benzoylamino)benzoylhydrazine was heated 
with substituted isothiocyanates under reflux for 2h in 
ethanol. The crude product was filtered and crystallized from 
ethanol (11).
5.2. General procedure for the preparation of 2-(4-aminophenyl)-
5-alkyl/arylamino-1,3,4-thiadiazoles (2g-l)
To 0.006 mol of 1a-l, 50% H2SO4  (15 mL) was added and the 
mixture and was refluxed for 5h at 110-150 oC. It was cooled 
and neutralized with 2N NaOH. The precipitate was filtered, 
washed with water and recrystallized from ethanol (11). 
5.2.1. 2-(4-Aminophenyl)-5-benzylamino-1,3,4-thiadiazole (2g) 
M.p. 225 oC, yield 58%, HPLC tR (min): 2.98; UV (EtOH, 
lmax, ): 326 (e 25470), 204 (e 29875) ; IR (KBr): 3425, 3307, 
3248, 3095, 1631, 1602, 1555, 1467, 1331, 826, 738 cm-1; 
1H-NMR (DMSO-d6, 400 MHz,  d): 4.48 (2H, s, -CH2-), 5.58 
(2H, s, -NH2), 6.58 (2H, d, J: 8.5 Hz protons in ortho position 
of aromatic primary amine), 7.18-7.40 (7H, m, Ar-H), 8.16 
(1H, s, -NH); MS (EI) m/z 282 (M+), 267, 257, 136, 135, 118, 
91, 77, 65, 63. Anal.calc. for C15H14N4S (282.26): C, 63.80; H, 
5.00; N, 19.84; S, 11.36 %. Found C, 63.95; H, 5.51; N, 18.80; 
S, 11.63%.
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5.2.2. 2-(4-Aminophenyl)-5-(4-fluorophenyl)amino-1,3,4-
thiadiazole (2h)
M.p.  193-195 oC; yield 63%; HPLC tR (min): 3.30; UV (EtOH, 
lmax,): 339 (e 3579), 231 (e 1717), 216, (e 2090); IR (KBr): 3412, 
3319, 3248, 3037, 1624, 1602, 1572, 1502, 1467, 1308, 1214  cm-
1; 1H-NMR (DMSO-d6, 400 MHz, d): 5.75 (2H, s, -NH2), 6.71 
(2H, d, J: 8.6 Hz protons in ortho position of aromatic primary 
amine), 7.28 (2H, t, J: 8.9 Hz  protons in ortho position of 
fluorine atom), 7.53 (2H, d, J: 8.6 Hz protons in meta position 
of aromatic primary amine), 7.67-7.76 (m, 2H,  protons in meta 
position of fluorine atom), 10.43 (1H, s, -NH-). Anal.calc. for 
C14H11FN4S. H2O (304.34): C, 55.25; H, 4.31; N, 18.41; S, 10.54 
%. Found C, 55.42; H, 3.80; N, 18.45; S, 11.05%.                                               
5.2.3. 2-(4-Aminophenyl)-5-(2-methylphenyl)amino-1,3,4-
thiadiazole (2i)
M.p. 183 oC;  yield 57 %; HPLC tR (min): 4.28; UV (EtOH, 
lmax,): 335 (e 24695), 205 (e 30137); IR (KBr):  3436, 3354, 
3225, 1636, 1608, 1590, 1531, 1496, 1461, 1331, 826, 750 
cm-1; 1H-NMR         (400 MHz, DMSO-d6 , d): 2.33 (3H, s, 
-CH3 ), 3.10-4.20 (2H, s, -NH2), 6.73 (2H, d, J: 8.4 Hz protons 
in ortho position of aromatic primary amine), 7.10 (1H, t, 
J: 7.5 Hz proton in meta position of –CH3), 7.28 (1H, t, J: 
8.3 Hz proton in para position of –CH3), 7.30 (1H, d, J: 8.0 
Hz proton in meta position of –CH3), 7.60 (2H, d, J: 8.0 Hz 
protons in meta  position of aromatic primary amine), 7.92 
(1H, d, J: 7.8 Hz proton in ortho position of –CH3), 9.20-9.70 
(s, -NH-); MS (EI) m/z 282 (M+), 263, 240, 210, 196, 165, 149, 
105, 91, 77, 69, 57. Anal.calc. for C15H14N4S. H2O (300.38): C, 
59.98; H, 5.37; N, 18.65; S, 10.67 %. Found C, 60.86; H, 5.36; 
N, 18.09; S, 10.44%. 
5.2.4. 2-(4-Aminophenyl)-5-(4-methylphenyl)amino-1,3,4-
thiadiazole (2j)
M.p. 217-218 oC;  yield 56 %; HPLC tR (min): 3.40; UV 
(EtOH, lmax,):  341 (e 35325), 259 (e 8866), 204 (e 37555) nm; 
IR (KBr): 3436, 3331, 3213, 2919, 1619, 1602, 1508, 1478, 
1437, 1325, 820, 738 cm-1; 1H-NMR (400 MHz, DMSO-d6 , d): 
2.42 (3H, s,–CH3), 5.61(2H, s, -NH2), 6.47  (2H,  d,  J: 8.5 Hz 
protons in ortho position of aromatic primary amine), 6.99 
(2H, d, J: 8.5 Hz protons in meta position of –CH3), 7.23 (2H, 
d, J: 8.1 Hz  protons in ortho position of –CH3), 7.39 (2H, d,  J: 
8.2 Hz protons in meta position of aromatic primary amine), 
13.84 (1H, s, -NH-); MS (EI) m/z 282 (M+), 280, 266, 249, 
223, 209, 195, 164, 119, 118, 106, 91, 77, 65, 63. Anal.calc. for 
C15H14N4S. ½ H2O  (291.37): C, 61.83; H, 5.19; N, 19.23; S, 
11.00%. Found C, 62.01; H, 5.13; N, 18.13; S, 11.23%. 
5.2.5. 2-(4-Aminophenyl)-5-(4-methoxyphenyl)amino-1,3,4-
thiadiazole (2k)
M.p. 255-257 oC; yield 41 %; HPLC tR (min): 2.21; UV (EtOH, 
lmax,):  337 (e 33749), 205 (e 39948) nm; IR (KBr): 3436, 3342, 
3236, 3142, 2966, 2931, 1631, 1608, 1514, 1461, 1437, 1331, 
1249, 1026, 832, 726 cm-1; 1H-NMR (400 MHz, DMSO-d6 , 
d): 3.87 (3H, s, -OCH3), 5.61 (2H, s, -NH2), 6.51 (2H, d, J: 
8.5 Hz protons in ortho position of aromatic primary amine), 
7.00 (2H, d, J: 8.6 Hz protons in ortho position of -OCH3), 
7.10 (2H, d, J: 8.9 Hz protons in  meta position of -OCH3), 
7.27 (2H, d, J: 8.9 Hz  protons in meta position of aromatic 
primary amine); MS (EI) m/z 298 (M+), 297, 282, 266, 225, 
165, 133, 118, 106, 91, 78, 68. Anal.calc. for C15H14N4O2S . ½ 
H2O (307.37): C, 58.61; H, 4.92; N, 18.23; S, 10.43%. Found 
C, 58.31; H, 4.45; N, 17.39; S, 10.62%.
5.2.6. 2-(4-Aminophenyl)-5-(4-nitrophenyl)amino-1,3,4-
thiadiazole (2ı)
M.p. > 300 oC; yield 47 %; HPLC tR (min):  3.28; UV (EtOH, 
lmax,):  375 (e 2890), 287 (e 23222), 205 (e 33319); IR (KBr): 
3483, 3401, 3330, 3049, 1614, 1514, 1461, 1331, 838, 750 cm-1; 
1H-NMR (400 MHz, DMSO-d6 , d): 5.83 (2H, s, -NH2), 6.69 
(2H, d, J: 8.6 Hz protons in ortho position of aromatic primary 
amine), 7.58 (2H, d, J: 8.6 Hz, protons in meta position of 
–NO2), 7.96 (2H, d, J: 7.2 Hz protons in meta position of 
aromatic primary amine), 8.33 (2H, d, J: 7.3 Hz protons in 
ortho position of –NO2), 11.02 (1H, s, -NH-). Anal.calc. for 
C14H11N5O2S (313.33): C, 53.66; H, 3.54; N, 22.35; S, 10.23 %. 
Found C, 53.25; H, 3.70; N, 22.28; S, 10.36%.
5.3. 2,3,4-Pentanetrione-3-[4-(5-alkyl/arylamino-1,3,4-
thiadiazole-2-yl)phenyl]hydrazone  ( 3a-j ) 
To a cooled solution of compounds 2a-l (0.01 mol) in 2 ml 
of hydrochloric acid (37%), an ice-cold solution of 10 mL of 
sodium nitrite (10%) were added. The reaction mixture was 
then poured into the mixture of 1 mL of acetylacetone and 
50 g of sodium acetate in ethanol (50%) by vigorous stirring. 
This mixture was allowed to stand in a refrigerator for 24 h. 
Precipitated solid was collected, washed with water, dried 
and washed with ethanol to give 3a-j (12).
5.3.1. 2,3,4-Pentanetrione-3-[4-(5-methylamino-1,3,4-
thiadiazole-2-yl)phenyl]hydrazone (3a)
M.p. 185-188 oC; yield 65 %; HPLC tR (min): 5.05;  UV 
(EtOH, lmax,):  393 (e 6116), 247 (e 1586), 208 (e 2135) ; IR 
(KBr):  3178, 1672, 1602, 1573, 1508, 1461, 1450, 1343, 1261, 
844, 768 cm-1; 1H-NMR (400 MHz, DMSO-d6 , d): 2.54 (3H, 
s, -COCH3), 2.64 (3H, s, -COCH3), 3.78 (3H, s, -NH-CH3), 
4.15 (1H, s, -NH-CH3), 7.54 (2H, d, J: 8.5 Hz protons in meta 
position of thiadiazole ring), 8.05 (2H, d, J: 8.5 Hz protons in 
ortho position  of thiadiazole ring), 14.68 (s, =N-NH-), MS 
(EI) m/z 317 (M+), 247, 205, 132, 118, 104, 88, 63. 
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5.3.2. 2,3,4-Pentanetrione-3-[4-(5-ethylamino-1,3,4-
thiadiazole-2-yl)phenyl]hydrazone (3b)
M.p. 178-180 oC; yield 63 %; HPLC tR (min): 10.76; UV 
(EtOH, lmax,):  398 (e 2485), 252 (e 397), 208 (e 563); IR 
(KBr): 2978, 2931, 1678, 1637, 1602, 1578, 1508, 1472, 1355, 
1267, 850, 750 cm-1; 1H-NMR (400 MHz, CDCI3 , d): 1.22-
1.75 (3H, 2t, -CH2-CH3), 2.54 (3H, s, -COCH3), 2.64 (3H, s, 
-COCH3), 4.33-5.20 (2H, 2q, -NH-CH2-),  7.53 (2H, d, J: 8.7 
Hz protons in meta position of thiadiazole ring), 8.04 (2H, t, 
J: 8.6 Hz protons in ortho position of thiadiazole ring), 14.69 
(1H, s, =N-NH-); MS (EI) m/z  331 (M+), 249, 248, 247, 220, 
219, 150, 149, 118, 92, 69, 63, 43. 
5.3.3. 2,3,4-Pentanetrione-3-[4-(5-propylamino-1,3,4-
thiadiazole-2-yl)phenyl]hydrazone (3c)
M.p. 166-168 oC;  yield 65 %; HPLC tR (min): 10.70; UV 
(EtOH, lmax,):  395 (e 23873), 286   (e 4491), 247 (e 7101); 
IR (KBr) 3619-3353, 3049, 2962-2923, 2865, 1676, 1600, 
1581, 1524, 1505, 1429, 822, 733 cm-1; 1H-NMR (400 MHz, 
CDCI3 , d):  0.91-1.09 (3H, 2t, -CH2-CH2-CH3), 1.64-2.19 
(2H, 2m, -CH2-CH2-CH3), 2.54 (3H, s, -COCH3), 2.64 (3H, 
s, -COCH3), 4.23-5.08 (2H, 2t, -CH2-CH2-CH3), 7.54 (d, 2H, 
J: 8.5 Hz protons in meta position of thiadiazole ring), 8.05 
(2H, t, J: 8.5 Hz protons in ortho position of thiadiazole ring), 
14.69 (s, =N-NH-), MS (EI) m/z 345 (M+), 303, 247, 234, 233, 
191, 141, 136, 135, 118, 116, 115, 103, 77, 73. 
5.3.4.  2,3,4-Pentanetrione-3-[4-(5-cyclohexylamino-1,3,4-
thiadiazole-2-yl)phenyl]hydrazone (3d)
M.p. 223 oC; yield 55 %; HPLC tR (min): 6.11; UV (EtOH, 
lmax,):  404 (e 43475), 298 (e 14563), 202 (e 23001); IR (KBr): 
3166, 3060, 2919, 2837, 1666, 1590, 1525, 1461, 1273, 844, 
750 cm-1; 1H-NMR (400 MHz, CDCI3, d): 1.00-2.23 (10H, 
m, cyclohexyl -CH2-), 2.51 (3H, s, -COCH3), 2.62   (3H, 
s, COCH3), 3.74  (1H, s, cyclohexyl –CH-), 5.39 (1H, s, 
-NH-), 7.45 (2H, d, J: 8.3 Hz protons in meta position 
of thiadiazole ring), 7.84 (2H, d, J: 8.0 Hz proton in ortho 
position of thiadiazole ring), 14.72 (s, =N-NH-). Anal.calc. 
for C19H23N5O2S. ½ H2O ( 394.49): C, 57.85; H, 6.13; N, 17.75; 
S, 8.13 %. Found C, 58.12; H, 5.95; N, 17.30; S, 8.24%. 
5.3.5. 2,3,4-Pentanetrione-3-[4-(5-phenylamino-1,3,4-
thiadiazole-2-yl)phenyl]hydrazone (3e)
M.p. 273 oC; yield 69 %; HPLC tR (min): 6.56; UV (EtOH, 
lmax,):  405 (e 41946), 309 (e 16109), 247 (e 16592), 203 (e 
33564). IR (KBr): 3243, 3194, 3077, 1673, 1567, 1503, 1442, 
1260, 836, 750 cm-1; 1H-NMR (400 MHz, DMSO-d6 , d): 2.57 
(6H, s, -COCH3), 7.09-7.93 (10H, m, Ar-H and –NH-), 13.81 
(s, =N-NH-); MS (EI) m/z 379 (M+), 303, 273, 246, 230, 191, 
157, 136, 135, 108, 90, 83, 67. Anal.calc. for C19H17N5O2S. 3/2 
H2O (406.46): C, 56.14; H, 4.96; N, 17.23; S, 7.89 %. Found C, 
56.51; H, 4.53; N, 16.13; S, 8.03%. 
5.3.6. 2,3,4-Pentanetrione-3-[4-[5(4-chlorophenyl)amino-
1,3,4-thiadiazole-2-yl)phenyl]hydrazone (3f)
M.p. 206-209 oC; yield 84 %; HPLC tR (min): 7.35; UV (EtOH, 
lmax,): 376 (e 29838), 204 (e 35632); IR (KBr): 3084, 2990, 
1689, 1525, 1490, 1437, 1261, 1085, 838, 750 cm-1; 1H-NMR 
(400 MHz, CDCI3 , d): 2.47 (3H,  s, -COCH3), 2.60 (3H, s, 
-COCH3), 7.18-7.51 (9H, m, Ar-H and –NH-), 14.62 (1H, s, 
=N-NH-); MS (CI) m/z 442 (M+C2H5)+, 414, 373, 331, 230, 
153, 114. Anal.calc. for C19H16ClN5O2S (413.88): C, 55.14; H, 
3.90; N, 16.92; S, 7.75 %. Found C, 54.94; H, 3.55; N, 17.00; 
S, 8.05%.
5.3.7. 2,3,4-Pentanetrione-3-[4-(5-benzylamino-1,3,4-
thiadiazole-2-yl)phenyl]hydrazone (3g)
M.p. 205 oC; yield 75 %; HPLC tR (min): 5.90; UV (EtOH, 
lmax,): 400 (e 5784), 298 (e 1967), 252 (e 1298), 210 (e 1770); 
IR (KBr): 3331, 3201, 3002, 1672, 1637, 1537, 1508, 1420, 
1296, 826, 767 cm-1; 1H-NMR (400 MHz, DMSO-d6 , d): 2.52 
(6H, s, -COCH3), 4.61 (2H, d, J: 5.8 Hz, -CH2-), 7.29-7.47 
(5H, m, -CH2-C6H5), 7.65 (2H, d, J: 8.7 Hz protons in meta 
position of thiadiazole ring), 7.88 (2H, d, J: 8.8Hz protons in 
ortho position of thiadiazole ring), 8.52 (1H, t, -NH-), 13.90 
(s, =N-NH-); MS (EI) m/z 393(M+), 384, 356, 346, 281, 258, 
250, 223, 161, 139, 133, 125, 122, 105, 91, 79, 77, 65, 57, 43. 
Anal.calc. for C20H19N5O2S (393.46): C, 61.05; H, 4.87; N, 
17.80; S, 8.15%. Found C, 61.41; H, 4.04; N, 16.83; S, 7.88%.
5.3.8.   2,3,4-Pentanetrione-3-[4-[5(4-fluorophenyl)amino-
1,3,4-thiadiazole-2-yl)phenyl]hydrazone (3h)
M.p. 165-168 oC; yield 52 %; HPLC tR (min): 5.31; UV (EtOH, 
lmax,): 372 (e 32193), 250 (e 15580), 214 (e 13195); IR (KBr): 
3084, 2998, 2974, 1674, 1606, 1594, 1576, 1478, 1263, 1166, 
763 cm-1; 1H-NMR (400 MHz, DMSO-d6 , d): 2.49 (3H, s, 
-COCH3), 2.53 (3H, s, -COCH3), 7.30-7.77 (8H, m, Ar-H), 
8.89 (s, -NH-), 13.81 (1H, s, =N-NH-); MS (EI) m/z 397(M+), 
366, 365, 322, 266, 254, 253, 226, 197, 184, 170, 136, 122, 118, 
109, 95, 82, 75, 70, 69. Anal.calc. for C19H16FN5O2S (397.43): 
C, 57.42; H, 4.06; N, 17.62; S, 8.07%. Found C, 58.36; H, 3.51; 
N, 16.94; S, 8.68%.   
5.3.9.    2,3,4-Pentanetrione-3-[4-[5(2-methylphenyl)amino-
1,3,4-thiadiazole-2-yl)phenylhydrazone (3i)
M.p. 217-219 oC; yield 59 %; HPLC tR (min): 7.55; UV (EtOH, 
lmax,): 397 (e 18314), 247 (e 6832), 213 (e 8084) nm; IR (KBr): 
3530-3331, 3178, 2919, 1666, 1631, 1584, 1555, 1508, 1461, 
1431, 1372, 1296, 785, 750 cm-1; 1H-NMR (400 MHz, CDCI3 
, d):  2.27 (s, Ar-CH3), 2.41 (s, -COCH3), 2.52 (s, -COCH3), 
7.11-7.82 (9H, m, Ar-H and –NH-), 14.30-14.75 (1H, =N-
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NH-); MS (EI) m/z 393(M+), 367, 356, 283, 282, 281, 250, 123, 
118, 105, 91, 78, 77, 65, 59, 51, 45. Anal.calc. for C20H19N5O2S. 
1/2 H2O (402.47): C, 59.68; H, 5.01; N, 17.40; S, 7.97%. Found 
C, 59.59; H, 4.91; N, 16.74; S, 8.01%.
5.3.10. 2,3,4-Pentanetrione-3-[4-[5(4-methylphenyl)amino-
1,3,4-thiadiazole-2-yl)phenyl]hydrazone (3j)
M.p. 242-244 oC; yield 63 %; HPLC tR (min): 6.06; UV (EtOH, 
lmax,):  373 (e 53512), 253 (e 2676), 211 (e 2400); IR (KBr): 
3084, 2919, 1684, 1649, 1578, 1508, 1437, 1355, 1302, 838, 
750   cm-1; 1H-NMR (400 MHz, DMSO- d6 , d): 2.42-2.46 
(CH3 protons were over shadow by DMSO peak), 6.46-8.07 
(9H, m, Ar-H and N-H), 13.02-14.46 (d and broad singlet 
,=N-NH-); MS (EI) m/z 393(M+), 295, 281, 282, 267, 265, 164, 
163, 149, 132, 118, 107, 91, 64. Anal.calc. for C20H19N5O2S 
(393.46): C, 61.05; H, 4.87; N, 17.80; S, 8.15 %. Found C, 
60.28; H, 4.59; N, 16.92; S, 8.57%.
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Bazı 2-(4-aminofenil)-5-sübstitüe amino-1,3,4-tiyadiazol 
türevlerinin ve kenetlenme ürünlerinin sentezi ve 
antimikobakterial etkileri
ÖZ
Bu çalışmada, çeşitli 2-(4-aminofenil)-5-sübstitüe amino-
1,3,4-tiyadiazoller (2a-l) ile onun kenetlenme ürünleri 
2,3,4-pentantrion-3-[4-(5-alkil/arilamino-1,3,4-tiyadiazol-
2-il)fenil]hidrazonlar (3a-j) yüksek verimlerle sentezlendi ve 
bileşiklerin yapıları UV, IR, 1H-NMR, kütle spektroskopisi 
ve elementel analiz yöntemleri kullanılarak aydınlatıldı. 
Bileşiklerin, in vitro Mycobacterium tuberculosis H37Rv suşuna 
karşı antimikobakteriyel etkileri BACTEC 460 Radyometrik 
Sistemi kullanılarak 6.25 μg/mL derişimde değerlendirildi. 
2-(4-Aminofenil)-5-(4-klorofenil)amino-1,3,4-tiyadiazol (2f) 
bileşiğinin en yüksek inhibisyon gösterdiği tespit edildi.
Anahtar kelimeler: 1,3,4-tiyadiazol, kenetlenme ürünleri, 
antimikobakteriyel etki
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